Little Neurotrope makes some big claims on another failed Alzheimer’s study, but shares collapse
A low profile, small biotech named Neurotrope $NTRP teased out a pocket of data from a small Phase II Alzheimer’s study which its investigators heralded as ‘positive.’
So why did its stock just plunge 53%?
Because the study failed, like virtually everything else that’s happened in Alzheimer’s R&D over the last 15 years.
To get to its “positive” nugget of data, investigators narrowed the field to a subgroup of moderate to severe patients who completed all six low doses of Bryostatin-1, designed to boost synapses in the brain that deteriorate rapidly in the disease, wreaking havoc in the brain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
